MAIA activates first U.S. site for Phase 2 THIO-101 trial in advanced NSCLC

MAIA Biotechnology, Inc.

First U.S. site activated at Summit Medical Group (NJ); four more U.S. sites planned in 2026.
44 active international sites across Europe/Asia; trial evaluates ateganosine as 3L NSCLC therapy.
$2.3M NIH grant funds third-line evaluation; holds FDA Fast Track designation.
2025 data: eight patients with overall survival beyond 2 years, four over 30 months, one at 33 months.
Approximately 50,000 advanced NSCLC patients in U.S. annually progress to third-line treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.